DAY 50

Health & Longevity: The Science of Medications
Why the "Standard Dose" Isn't Yours

2026-07-06 · BigCat's Vitality Protocol
Evidence base this issue: regulatory standards, CPIC / Beers guidelines, and cohort / meta-analyses — focused on the personalized question, "what will this drug do in you?"
SUB · Pharmacogenomics / Personalized Dosing
Individual Variation in Drug Metabolism: Why the "Standard Dose" Is a Population Average
Pharmacogenomics — Same Dose, Different Blood Levels
One-Line Takeaway
The same dose of the same drug can produce blood levels that differ several-fold between people. The main driver is genetic polymorphism in liver CYP450 enzymes — the "standard dose" is a population average, not necessarily optimal for you. For a few high-risk drugs, genotyping before you start can be lifesaving.
Evidence Level
Mechanistic + cohort + clinical guidelines. CPIC (Clinical Pharmacogenetics Implementation Consortium) publishes graded, gene–drug dosing guidance for dozens of pairs. Classic cases: CYP2C19 poor metabolizers respond poorly to clopidogrel (higher stent-thrombosis risk — FDA boxed warning); CYP2D6 ultrarapid metabolizers convert codeine to morphine too fast, which caused fatal post-operative respiratory depression in children — since 2013 the FDA bars codeine in children after tonsillectomy/adenoidectomy.
Science + Mechanism
The CYP450 enzyme family metabolizes roughly 70–80% of clinical drugs. Polymorphisms sort people into poor / intermediate / normal / ultrarapid metabolizers: poor metabolizers accumulate drug and are prone to toxicity; ultrarapid metabolizers may find a drug "does nothing." These differences determine blood levels more than body weight does, yet stay invisible until exposed by a gene test or drug-level assay.
Actionable Protocol
DrugLinked GeneWhy Test
WarfarinCYP2C9 / VKORC1Predict starting dose, reduce bleeding
ClopidogrelCYP2C19Poor metabolizers need a switch
Azathioprine / 6-MPTPMT / NUDT15Prevent severe myelosuppression
AllopurinolHLA-B*58:01Prevent fatal drug rash
CarbamazepineHLA-B*15:02High Han-Chinese carrier rate; prevent SJS/TEN
Principle: before starting the high-risk drugs above, discuss genotyping with your doctor (especially allopurinol and carbamazepine in East Asian populations). Don't blanket-test every drug — spend where the evidence is strong and the consequences are severe.
Women's Note + Common Myths
Many "standard doses" were set in male subjects, yet women are on average lighter, have a higher body-fat fraction, and clear some drugs more slowly. Classic case: the sleep drug zolpidem — because next-day residue posed a driving risk in women, the FDA in 2013 specifically halved the female starting dose (10 → 5 mg).
Myth 1: "Dosing by body weight is precise enough" — enzyme-activity differences often matter more than weight.
Myth 2: "If it worked for someone else with this drug, it'll work for me" — different metabolizer types can mean completely different efficacy and side effects.
Key References
• Relling MV, Klein TE. CPIC Guidelines. Clin Pharmacol Ther (series)
• Scott SA, et al. CYP2C19 & clopidogrel. Clin Pharmacol Ther. 2013
• FDA Drug Safety Communications: codeine (2013), zolpidem (2013)
Try This Week + Reflection
THIS WEEK
List the prescription drugs you or a family member take long-term, and check whether any fall on a "high-evidence pharmacogenomics" list like the table above. If so, at the next visit ask: "Does this drug need a gene test first?"
Reflection: if doses could be personalized, why does the system still default to one-size-fits-all? Cost, evidence, or habit?
SUB · Polypharmacy / Deprescribing
Polypharmacy: More Drugs Don't Mean Better Health
Polypharmacy — When More Drugs Cause Harm
One-Line Takeaway
Taking ≥5 drugs long-term is "polypharmacy," and the risk of adverse reactions, falls, and hospitalization rises nearly linearly with the drug count. In older adults, active "deprescribing" is itself an evidence-based intervention.
Evidence Level
Cohort + RCT + expert consensus. The AGS Beers Criteria (2023 update) and Europe's STOPP/START list drugs older adults should avoid / consider. Multiple cohorts link drug count to falls, cognitive decline, and ER visits. Deprescribing RCTs show that supervised withdrawal of unnecessary drugs can safely reduce adverse events.
Science + Mechanism
Harm arrives by three routes: drug interactions (CYP inhibition/induction, additive QT prolongation); anticholinergic burden (stacked sleep aids, antihistamines, incontinence drugs → constipation, confusion, falls, cognitive decline); and the prescribing cascade — one drug's side effect is mistaken for a new disease and treated with another drug, snowballing. In older adults, reduced hepatic/renal clearance means the same dose yields higher exposure.
Actionable Protocol
• Keep a full list: photograph or write down every prescription drug + OTC + supplement, and carry it
• Regular medication reconciliation: at every doctor change / discharge / every six months, have a physician or pharmacist review each item
• Ask yourself four questions: Do I still need this? Is there an end point? Can the dose come down? Is there a safer alternative?
• Beware anticholinergics: older adults should minimize first-gen antihistamines (diphenhydramine) as sleep aids, and some incontinence drugs
• Deprescribe one at a time, slowly, supervised — never stop abruptly on your own (especially steroids, anti-epileptics, psychiatric drugs)
Women's Note + Common Myths
Older women tend to take more drug types, and on a baseline of osteoporosis, sedatives / anticholinergics stack the fall → fracture risk more dangerously. When perimenopausal insomnia and mood layer on multiple drugs, reconcile regularly rather than just adding more.
Myth 1: "A doctor prescribed it, so I must take it forever" — many drugs have a defined course; reassess when circumstances change.
Myth 2: "Supplements don't count as drugs, so I can add freely" — St. John's Wort induces CYP3A4 and lowers the blood levels of contraceptives, anticoagulants, and immunosuppressants.
Key References
• 2023 AGS Beers Criteria. J Am Geriatr Soc. 2023
• O'Mahony D, et al. STOPP/START v3. Eur Geriatr Med. 2023
• Scott IA, et al. Deprescribing. JAMA Intern Med. 2015
Try This Week + Reflection
THIS WEEK
Do one thing for yourself or an older relative: photograph everything being taken (prescriptions, OTC, supplements) into a single "family portrait," and hand it to a doctor or pharmacist at the next visit for a medication reconciliation.
Reflection: "adding a drug" is nearly frictionless, "removing a drug" takes courage and time — how does that asymmetry shape overprescribing?
SUB · Generics / Bioequivalence
Generic Drugs: Cheaper Doesn't Mean Discounted Efficacy
Generic Drugs — Cheaper, Not Weaker
One-Line Takeaway
A compliant generic is bioequivalent to the brand: same active ingredient, same dose, no clinical difference in efficacy — often at 80%+ lower price. For drugs, "expensive = better" mostly doesn't hold.
Evidence Level
Regulatory standards + meta-analysis. FDA bioequivalence requires that the 90% confidence interval of the AUC/Cmax geometric-mean ratio fall within 80–125% of the brand. Kesselheim et al. 2008 (JAMA) pooled RCTs of cardiovascular generics vs. brand and found no clinical efficacy difference. China's recent "generic consistency evaluation" follows the same logic.
Science + Mechanism
After patent expiry, a generic need only prove identical active ingredient + bioequivalence — no need to repeat expensive large trials. That's why it's cheap, not because corners were cut. "80–125%" is widely misread: it does not mean "efficacy may vary by 20%," but rather the confidence-interval bounds of the mean exposure ratio; in practice the two means are usually very close. Differences come mainly from excipients (dyes, lactose); rarely, someone may not tolerate a given excipient.
Actionable Protocol
• Default to generics: for the vast majority of chronic-disease drugs (statins, antihypertensives, metformin), generics are safe and the savings add up
• Narrow-therapeutic-index drugs warrant care: warfarin, levothyroxine, anti-epileptics, immunosuppressants — no panic, but when switching manufacturers/formulations, monitor the relevant markers or blood levels, and report anything unusual to your pharmacist
• Use legitimate channels; avoid dubious "authentic imports"
Women's Note + Common Myths
Hypothyroidism is more common in women, and many take levothyroxine long-term — a narrow-therapeutic-index drug. After switching manufacturer or formulation, recheck TSH at 6–8 weeks before re-setting the dose, rather than judging by feel that "the switched drug is bad."
Myth 1: "Generics are only 80% as effective as the brand" — a typical misreading of the bioequivalence interval.
Myth 2: "Imported / brand is always better" — for most mature drugs, the clinical evidence doesn't support the premium.
Key References
• Kesselheim AS, et al. JAMA. 2008;300(21):2514-2526
• FDA. Orange Book / Bioequivalence standards
• NMPA generic quality-and-efficacy consistency evaluation (policy)
Try This Week + Reflection
THIS WEEK
Pick one common drug you take long-term and check whether a consistency-evaluated generic exists; at your next refill, ask the pharmacist about switching and estimate a year's savings.
Reflection: given comparable clinical evidence, what makes people willing to pay several times more for a "brand" — a sense of safety, anchoring, or information asymmetry?
SUB · Supplement Regulation / Quality
Supplement Regulation: Barely Vetted Before Sale, Labels Often Untrustworthy
Supplement Regulation — The Wild West of the Pill Aisle
One-Line Takeaway
In most countries, dietary supplements need not prove efficacy or safety before sale (the US DSHEA 1994 classes them as food). Oversight is far looser than for drugs; label content often doesn't match reality, and adulteration and contamination are real.
Evidence Level
Regulatory analysis + testing studies. DSHEA leaves the FDA to regulate only after a product is on the market — recalls come after harm. Cohen and others have repeatedly found supplement contents mismatching labels, even spiked with prescription drugs (weight-loss products with sibutramine, "male-enhancement" ones with sildenafil). Geller et al. 2015 (NEJM) estimated ~23,000 supplement-related ER visits per year in the US.
Science + Mechanism
No pre-market approval → uneven quality and inflated claims. A "proprietary blend" can legally hide the dose of each ingredient, so you can't tell whether it's an effective amount or an overdose. Some herbs carry real hepatotoxicity risk (kava, high-dose green-tea extract, Fo-Ti / Polygonum multiflorum). Third-party certification is currently the most practical quality filter.
Actionable Protocol
• Food first: don't rely on pills for nutrients you can get from diet (see Day 9, Supplement Science)
• Look for third-party certification: USP, NSF, NSF Certified for Sport, ConsumerLab — verifying identity, content, and contamination
• Avoid red flags: "proprietary blends" that hide doses, exaggerated "detox / fat-burn / immune-boost" claims, results that seem too good to be true
• Beware hepatotoxic herbs: fatigue, jaundice, or dark urine → stop immediately and seek care; before surgery, or when trying to conceive / pregnant, proactively tell your doctor
Women's Note + Common Myths
Pregnancy demands extra caution: some herbs can be teratogenic or trigger contractions, and safety data are often missing. Iron, calcium, and vitamin D should be supplemented based on test results, not "more can't hurt" — iron overload is also harmful. Claims for perimenopausal "natural estrogen" supplements mostly lack strong evidence.
Myth 1: "Natural = safe" — poisonous mushrooms are natural too (see Day 45, Traditional Medicine).
Myth 2: "Supplements have no side effects, so take extra to be safe" — excess fat-soluble vitamins, adulterated products, and herbal hepatotoxicity are all real harms.
Key References
• Geller AI, et al. N Engl J Med. 2015;373(16):1531-1540
• Cohen PA. JAMA Intern Med. (supplement-adulteration series)
• US DSHEA 1994; USP / NSF certification standards
Try This Week + Reflection
THIS WEEK
Dig out the supplement bottles at home and look for a USP or NSF mark, and for any "proprietary blend" that doesn't list per-ingredient doses. Toss the ones with no evidence and no certification.
Reflection: when a product is "food by regulation, drug by perception," how is that identity mismatch exploited by marketing?

Deeper Reflection

① If pharmacogenomics can predict efficacy and toxicity, why isn't it routine testing?
The barriers are many: for most common drugs, genes explain only part of the variation, so the cost-benefit is weak; testing, interpretation, EHR integration, and insurance coverage are all immature; clinician training and workflows haven't caught up. The pragmatic path today is targeted testing — mandating or recommending it only for gene–drug pairs with strong evidence and severe consequences (e.g., allopurinol HLA-B*58:01, carbamazepine HLA-B*15:02), rather than whole-genome screening for everyone.
② Deprescribing is beneficial on the evidence, so why is it so hard in practice?
Adding a drug is nearly frictionless; removing one carries the responsibility and time cost of "what if I stopped the wrong thing," and that asymmetry systematically biases toward overprescribing. Fragmented care (multiple specialists each prescribing, no one holding the whole picture), the patient's "I feel safer with a pill" psychology, and the lack of reimbursement incentives for deprescribing all entrench the status quo. The fix requires someone explicitly owning "oversight of the whole regimen" — usually a GP or clinical pharmacist.
③ One and the same pill is tightly regulated as a drug yet barely touched as a supplement — what does this gap mean?
The burden of proof is reversed: for drugs, "the maker must prove safety and efficacy before sale"; for supplements, "the regulator must prove harm after the fact before removal." The consumer ends up bearing the risk-verification that should be the maker's. Individuals can hedge only two ways — treat supplements as "risky interventions" to take seriously, and let third-party certification stand in for the missing regulator.
← Back to Index